Stay updated on Pembrolizumab/Lenvatinib vs Docetaxel in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab/Lenvatinib vs Docetaxel in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab/Lenvatinib vs Docetaxel in NSCLC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedAdded Revision: v3.3.3 and removed HHS Vulnerability Disclosure and Revision: v3.3.2.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check30 days agoChange DetectedRevision history now shows an addition of Revision: v3.3.2 and removal of Revision: v3.2.0.SummaryDifference0.0%

- Check37 days agoChange DetectedThe page removed a government funding notice, which is a minor administrative change and does not affect the study record or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check59 days agoChange DetectedA new version entry was added to the Record History, showing an updated submission date. No core study data appear to be altered.SummaryDifference0.0%

- Check80 days agoChange Detected- Added a government-operation notice and status links, clarifying potential delays and current NIH Clinical Center openness. - Removed the previous version tag (v3.1.0) and introduced v3.2.0.SummaryDifference7%

- Check88 days agoChange DetectedVersion bump from v3.0.2 to v3.1.0; no other content changes detected.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab/Lenvatinib vs Docetaxel in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab/Lenvatinib vs Docetaxel in NSCLC Clinical Trial page.